UGN-103 Regulatory Path -- Submission is targeted for 2026, with expectation of FDA approval in 2027; FDA is anticipated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback